Enlivex Ltd. (Bio Blast Pharma Ltd.) Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Bio Blast Pharma Ltd. (also referred to as Enlivex Ltd.) on February 10, 2015, for the month of February 2015. The filing serves to distribute the Notice of Meeting, Proxy Statement, and Proxy Card for an Extraordinary General Meeting of Shareholders scheduled for March 18, 2015.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notice rather than a financial results report.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this filing. The primary event is the convening of a shareholder meeting.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, outlook, risks, contingencies, or unusual items. It strictly outlines the logistics for the upcoming shareholder vote.
Key Facts for Investors to Verify
- Meeting Date: The Extraordinary General Meeting is set for Wednesday, March 18, 2015.
- Record Date: Shareholders of record holding Ordinary Shares (nominal value NIS 0.01) at the close of trading on the Nasdaq Global Market on February 18, 2015, are entitled to vote.
- Document Reference: Detailed proposals and voting instructions are contained in Exhibit 99.1 (Notice of Meeting, Proxy Statement, and Proxy Card).
- Company Status: The registrant files annual reports under Form 20-F.